20 Dec 2017 13:50
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 30 November 2017
Net Assets | £227m |
Net Assets per share | 603p |
Share price | 609p |
Total value of unquoted investments | £19m |
Total number of portfolio companies | 93 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Biogen | 7.5 |
Celgene | 5.4 |
Adamas | 5.3 |
Regeneron | 4.8 |
Nektar | 4.0 |
Vertex | 4.0 |
Exelixis | 3.9 |
Acadia | 3.3 |
Gilead | 3.0 |
Genmab | 2.9 |
| ----------- |
Total | 44.1 |
Geographical Allocation | % NAV |
US & Canada | 90 |
Europe & UK | 10 |
| ----------- |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 92 |
Unquoted | 8 |
| ----------- |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 28 |
Mid Cap =USD1-10BN | 36 |
Small Cap | 36 |
| ----------- |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 40 |
CNS | 13 |
Rare diseases | 11 |
Inflammation | 8 |
Ophthalmology | 7 |
Infectious Diseases | 6 |
Metabolic | 4 |
Medtech | 2 |
Other | 9 |
| ----------- |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
20 DECEMBER 2017